Senti Biosciences (SNTI) Competitors

$0.88 -0.06 (-6.35%)

Closing price 04:00 PM Eastern

Extended Trading

$0.89 +0.01 (+0.98%)

As of 07:55 PM Eastern

SNTI vs. THAR, ACOG, TTRX, EDSA, and PEPG

Should you buy Senti Biosciences stock or one of its competitors? MarketBeat compares Senti Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Senti Biosciences include Tharimmune (THAR), Alpha Cognition (ACOG), Turn Therapeutics (TTRX), Edesa Biotech (EDSA), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry.

How does Senti Biosciences compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Tharimmune has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

Senti Biosciences' return on equity of -532.05% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Senti Biosciences	N/A	-532.05%	-103.35%

In the previous week, Senti Biosciences had 15 more articles in the media than Tharimmune. MarketBeat recorded 17 mentions for Senti Biosciences and 2 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.00 beat Senti Biosciences' score of -0.11 indicating that Tharimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tharimmune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Senti Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Senti Biosciences has a consensus target price of $8.75, suggesting a potential upside of 893.87%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tharimmune has higher earnings, but lower revenue than Senti Biosciences. Tharimmune is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Senti Biosciences	$38K	721.56	-$61.44M	-$1.92	N/A

Summary

Senti Biosciences beats Tharimmune on 12 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Alpha Cognition has higher revenue and earnings than Senti Biosciences. Alpha Cognition is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.83M	11.67	-$20.67M	-$1.35	N/A
Senti Biosciences	$38K	721.56	-$61.44M	-$1.92	N/A

In the previous week, Senti Biosciences had 10 more articles in the media than Alpha Cognition. MarketBeat recorded 17 mentions for Senti Biosciences and 7 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 0.49 beat Senti Biosciences' score of -0.11 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Senti Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alpha Cognition presently has a consensus target price of $16.00, indicating a potential upside of 175.86%. Senti Biosciences has a consensus target price of $8.75, indicating a potential upside of 893.87%. Given Senti Biosciences' higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

25.7% of Senti Biosciences shares are held by institutional investors. 14.0% of Alpha Cognition shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Senti Biosciences has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Senti Biosciences	N/A	-532.05%	-103.35%

Alpha Cognition has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Summary

Alpha Cognition beats Senti Biosciences on 9 of the 17 factors compared between the two stocks.

How does Senti Biosciences compare to Turn Therapeutics?

Senti Biosciences (NASDAQ:SNTI) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

In the previous week, Senti Biosciences had 11 more articles in the media than Turn Therapeutics. MarketBeat recorded 17 mentions for Senti Biosciences and 6 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.53 beat Senti Biosciences' score of -0.11 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Senti Biosciences currently has a consensus target price of $8.75, indicating a potential upside of 893.87%. Turn Therapeutics has a consensus target price of $8.00, indicating a potential upside of 75.82%. Given Senti Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Turn Therapeutics' return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Turn Therapeutics	N/A	N/A	N/A

25.7% of Senti Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Turn Therapeutics has lower revenue, but higher earnings than Senti Biosciences. Turn Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$38K	721.56	-$61.44M	-$1.92	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

Summary

Senti Biosciences beats Turn Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Senti Biosciences compare to Edesa Biotech?

Senti Biosciences (NASDAQ:SNTI) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Senti Biosciences has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Edesa Biotech has lower revenue, but higher earnings than Senti Biosciences. Edesa Biotech is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$38K	721.56	-$61.44M	-$1.92	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Edesa Biotech's return on equity of -286.52% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Edesa Biotech	N/A	-286.52%	-75.36%

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Senti Biosciences currently has a consensus price target of $8.75, indicating a potential upside of 893.87%. Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 58.16%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Senti Biosciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Senti Biosciences had 7 more articles in the media than Edesa Biotech. MarketBeat recorded 17 mentions for Senti Biosciences and 10 mentions for Edesa Biotech. Senti Biosciences' average media sentiment score of -0.11 beat Edesa Biotech's score of -0.42 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Edesa Biotech	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Senti Biosciences beats Edesa Biotech on 10 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to PepGen?

Senti Biosciences (NASDAQ:SNTI) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Senti Biosciences has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$38K	721.56	-$61.44M	-$1.92	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

In the previous week, Senti Biosciences had 7 more articles in the media than PepGen. MarketBeat recorded 17 mentions for Senti Biosciences and 10 mentions for PepGen. PepGen's average media sentiment score of 1.12 beat Senti Biosciences' score of -0.11 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
PepGen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Senti Biosciences has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, PepGen has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

PepGen's return on equity of -59.89% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
PepGen	N/A	-59.89%	-49.62%

Senti Biosciences currently has a consensus target price of $8.75, suggesting a potential upside of 893.87%. PepGen has a consensus target price of $11.60, suggesting a potential upside of 740.58%. Given Senti Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Senti Biosciences is more favorable than PepGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Senti Biosciences beats PepGen on 9 of the 15 factors compared between the two stocks.

Get Senti Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNTI vs. The Competition

Export

Metric	Senti Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.42M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-0.46	18.70	20.58	25.09
Price / Sales	721.56	278.20	577.42	91.07
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	4.89	6.57	9.68	6.60
Net Income	-$61.44M	$24.30M	$3.55B	$335.71M
7 Day Performance	-9.24%	-3.56%	-2.07%	-2.03%
1 Month Performance	-19.96%	-7.86%	-3.90%	-1.90%
1 Year Performance	-72.83%	51.80%	29.39%	27.36%

Senti Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNTI Senti Biosciences	2.3425 of 5 stars	$0.88 -6.4%	$8.75 +893.9%	-70.4%	$29.28M	$20K	N/A	4	Earnings Report Analyst Revision
THAR Tharimmune	0.0068 of 5 stars	$3.19 +5.6%	N/A	+172.2%	$120.36M	N/A	N/A	2	News Coverage
ACOG Alpha Cognition	4.2109 of 5 stars	$5.49 -7.7%	$16.00 +191.4%	-33.5%	$119.52M	$10.22M	N/A	N/A	Earnings Report Gap Down
TTRX Turn Therapeutics	3.0062 of 5 stars	$3.98 +2.6%	$8.00 +101.0%	N/A	$118.56M	N/A	N/A	2	News Coverage Positive News
EDSA Edesa Biotech	1.4134 of 5 stars	$13.27 -13.2%	$5.00 -62.3%	+343.3%	$117.97M	N/A	N/A	20	News Coverage Earnings Report Analyst Downgrade Short Interest Increase Gap Up Trading Halted

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNTI) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Senti Biosciences (SNTI) Competitors

SNTI vs. THAR, ACOG, TTRX, EDSA, and PEPG

How does Senti Biosciences compare to Tharimmune?

Summary

How does Senti Biosciences compare to Alpha Cognition?

Summary

How does Senti Biosciences compare to Turn Therapeutics?

Summary

How does Senti Biosciences compare to Edesa Biotech?

Summary

How does Senti Biosciences compare to PepGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Senti Biosciences (SNTI) Competitors

SNTI vs. THAR, ACOG, TTRX, EDSA, and PEPG

How does Senti Biosciences compare to Tharimmune?

Which has more volatility and risk, THAR or SNTI?

Is THAR or SNTI more profitable?

Does the media prefer THAR or SNTI?

Do analysts prefer THAR or SNTI?

Do insiders and institutionals hold more shares of THAR or SNTI?

Which has stronger valuation & earnings, THAR or SNTI?

Summary

How does Senti Biosciences compare to Alpha Cognition?

Which has stronger valuation & earnings, ACOG or SNTI?

Does the media refer more to ACOG or SNTI?

Do analysts prefer ACOG or SNTI?

Do insiders & institutionals have more ownership in ACOG or SNTI?

Is ACOG or SNTI more profitable?

Which has more volatility & risk, ACOG or SNTI?

Summary

How does Senti Biosciences compare to Turn Therapeutics?

Does the media favor SNTI or TTRX?

Do analysts rate SNTI or TTRX?

Is SNTI or TTRX more profitable?

Do institutionals and insiders have more ownership in SNTI or TTRX?

Which has preferable earnings & valuation, SNTI or TTRX?

Summary

How does Senti Biosciences compare to Edesa Biotech?

Which has more risk & volatility, SNTI or EDSA?

Which has higher valuation & earnings, SNTI or EDSA?

Is SNTI or EDSA more profitable?

Do institutionals and insiders hold more shares of SNTI or EDSA?

Do analysts recommend SNTI or EDSA?

Does the media favor SNTI or EDSA?

Summary

How does Senti Biosciences compare to PepGen?

Which has higher earnings & valuation, SNTI or PEPG?

Does the media prefer SNTI or PEPG?

Do institutionals & insiders hold more shares of SNTI or PEPG?

Which has more risk & volatility, SNTI or PEPG?

Is SNTI or PEPG more profitable?

Do analysts rate SNTI or PEPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools